Table of Contents

July 01, 2011; Volume 78, Issue 7
  • From the Editor

      • When good drugs turn weirdly bad

        Brian F. Mandell, MD, PhD
        • Cleveland Clinic Journal of Medicine July 2011, 78 (7) 426;
        • DOI: https://doi.org/10.3949/ccjm.78b.11007
        • Even the most specific of drugs, such as interferon, can have untoward biologic effects.

  • Medical Grand Rounds

  • Review

      • Hypothermia after cardiac arrest: Beneficial, but slow to be adopted

        Santosh Samuel Oommen, MD and Venu Menon, MD
        • Cleveland Clinic Journal of Medicine July 2011, 78 (7) 441-448;
        • DOI: https://doi.org/10.3949/ccjm.78a.10157
        • Survivors of cardiac arrest due to ventricular tachycardia or ventricular fi brillation have better neurologic outcomes if they are cooled to a core body temperature of 32°C to 34°C for 24 hours as soon as possible after reaching the hospital.

  • Cancer Diagnosis and Management

      • Managing cancer pain: Frequently asked questions

        Raghava R. Induru, MD and Ruth L. Lagman, MD, MPH, FACP
        • Cleveland Clinic Journal of Medicine July 2011, 78 (7) 449-464;
        • DOI: https://doi.org/10.3949/ccjm.78a.10054
        • Cancer pain: its pathogenesis, how to assess it, and how to treat it—in particular, how to use opioids optimally.

  • Current Drug Therapy

      • Vancomycin: A 50-something-yearold antibiotic we still don’t understand

        Amy Schilling, PharmD, Elizabeth Neuner, PharmD and Susan J. Rehm, MD
        • Cleveland Clinic Journal of Medicine July 2011, 78 (7) 465-471;
        • DOI: https://doi.org/10.3949/ccjm.78a.10168
        • To use vancomycin appropriately, we need to recognize its changing minimum inhibitory concentrations, select proper doses and dosing intervals, and know how to monitor its use.

  • The Clinical Picture

      • Rash from hepatitis C treatment

        Derek M. Tang, MD and Lawrence Ward, MD, MPH
        • Cleveland Clinic Journal of Medicine July 2011, 78 (7) 472-474;
        • DOI: https://doi.org/10.3949/ccjm.78a.10124
        • Although the combination of interferon and ribavirin is the standard of treatment for chronic hepatitis C, some patients experience adverse reactions.

  • Editorial

      • Bronchial thermoplasty: A promising therapy, still in its infancy

        Amit K. Mahajan, MD and D. Kyle Hogarth, MD, FCCP
        • Cleveland Clinic Journal of Medicine July 2011, 78 (7) 475-476;
        • DOI: https://doi.org/10.3949/ccjm.78a.11063
        • Inflammation is not the only pathophysiologic process underlying asthma. Bronchial thermoplasty takes a novel approach and offers reason for optimism.

  • Review

      • TOC Icon

        Bronchial thermoplasty: A new treatment for severe refractory asthma

        Thomas R. Gildea, MD, MS, Sumita B. Khatri, MD, MS and Mario Castro, MD, MPH
        • Cleveland Clinic Journal of Medicine July 2011, 78 (7) 477-485;
        • DOI: https://doi.org/10.3949/ccjm.78a.10185
        • Asthma has a new treatment, but it isn’t for everybody. Here, we review its indications, evidence of efficacy, and protocols.